FZD2 and breast carcinoma: Knockout of Fzd2 significantly reduced the expression of ABC transporter subfamily G isoform 2 (ABCG2) and IC50 of paclitaxel, indicating that knockout of Fzd2 enhanced the sensitivity of breast cancer cells to paclitaxel.